DSIP (delta sleep-inducing peptide) is a nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) originally identified by Marcel Monnier's laboratory in Basel, Switzerland, in 1977 through the classical dialysate-transfusion approach — inducing sleep in one rabbit by dialysing cerebral venous blood into another rabbit and identifying the sleep-inducing bioactive component.

The compound was one of the first sleep-related peptides to be characterised and became a substantial research target across international sleep-research groups through the late 1970s, 1980s, and 1990s. It provides the classical foundational reference for the wider sleep-architecture peptide research programme.

The DSIP sleep-architecture evidence base uses standard polysomnographic (PSG) endpoints — total sleep time, sleep-onset latency, slow-wave-sleep (SWS) duration, REM sleep duration, sleep-efficiency measures, and subjective sleep-quality scores. Assessment protocols use overnight sleep-lab PSG recording paired with DSIP administration (parenteral or intranasal) in evening dosing.

Study populations included healthy volunteers, insomnia patients, and specific clinical populations including chronic-pain patients (where sleep disturbance is a comorbid issue) and drug-withdrawal patients (where DSIP was explored as an adjunct sleep-restoration intervention).

The evidence base showed mixed and inconsistent effects on the standard PSG sleep-architecture endpoints. Some studies reported modest improvements in slow-wave-sleep duration and sleep-efficiency measures; other studies reported null effects on the same measures in similar populations.

Subjective sleep-quality scores were more consistently reported as improved, though the interpretation of subjective versus objective sleep-endpoint discrepancies is a persistent methodological difficulty in sleep research generally.

Specific patient-population subgroups (chronic-pain patients with comorbid sleep disturbance) showed somewhat more consistent positive effects; healthy-volunteer populations showed the most inconsistent effects. Effect-size magnitude when positive was typically modest.

Several caveats are appropriate when interpreting the DSIP evidence base. First, the mixed replicability across research groups and study populations is a persistent finding — the compound has not shown the consistency of effect that would support licensed-indication development.

Second, the classical evidence base predates modern sleep-research methodological standards. Trial designs, blinding, and endpoint standardisation are variable relative to what is now expected in a Cochrane-standard sleep-research evidence base.

Third, the compound's chemistry (short plasma half-life, questionable CNS penetration via peripheral administration) provides a plausible mechanistic explanation for the inconsistent effect-size — inadequate CNS exposure via peripheral administration would produce exactly the mixed-effect pattern observed.

The classical DSIP sleep-architecture research programme provides historically-significant reference for the peptide sleep-research field and continues to motivate research interest in sleep-related peptide compounds. The compound's specific evidence base is not, however, strong enough to support licensed-indication clinical use, and current sleep-medicine practice does not include DSIP.

For research purposes the classical DSIP research provides useful methodological reference for the wider sleep-related peptide research context. For clinical purposes DSIP is a research chemical without licensed medicinal use in any major jurisdiction; the popular use of DSIP in sleep-support contexts is not supported by clinical-evidence standards.